Stifel and FBR Capital analysts came out today with new ratings and price targets on a handful of healthcare stocks. Lets take a look and see what they have to say about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and TG Therapeutics Inc (NASDAQ:TGTX).
Valeant Pharmaceuticals Intl Inc
After joining Stifel healthcare equity research team in July, analyst Adam Walsh initiated coverage on shares of Valeant Pharma, with a Buy rating and price target of $160, which represents a potential upside of 62% from where the stock is currently trading.
In explaining his positive Buy rating Walsh stated, “With Orkambi ramping, Kalydeco still growing, and a host of new pipeline medicines steadily marching toward/through the clinic, Vertex remains well positioned to sustain and expand its dominant leadership position in cystic fibrosis (CF), in our view. In addition, we think the omnipresent prospect of a Vertex take-out puts a floor under shares near current levels.”
“Near term, the Orkambi launch will likely remain in focus, and our recent checks with multiple CF key opinion leader (KOL) physicians and the lead medical director of a major U.S. payer suggest uptake remains steady, and the payer environment is relatively benign,” the analyst added.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Adam Walsh has a total average return of 22% and a 54% success rate. Walsh is ranked #374 out of 3644 analysts.
Out of the 21 analysts polled by TipRanks in the last 3 months, 14 rate Valeant Pharmaceuticals stock a Buy, 6 rate the stock a Hold and 1 recommends a Sell. With a return potential of 61.02%, the stock’s consensus target price stands at $159.06.
TG Therapeutics Inc
Additionally, FBR Capital analyst Edward White initiated coverage on shares of TG Therapeutics, with an Outperform rating and price target of $29, which implies an upside of 104.5% from current levels.
White wrote, “TG-1101 is a monoclonal antibody, and TGR-1202 is a PI3K delta inhibitor. Both have posted strong safety data in studies to date. Safety is an important component for developing combination therapies. We believe the safety and efficacy of the two drugs will enable them to be part of triple and even quadruple combinations for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). TG-1101 may also have a future in the autoimmune disease area. We expect a Phase II dose-ranging study to begin in 2016 in multiple sclerosis and could even see a Phase III trial start in this indication by the end of 2016.”
According to TipRanks.com, analyst Edward White has a total average return of -22.1% and a 30.0% success rate. White is ranked #3450 out of 3644 analysts.